Home » Stocks » IPIX

Innovation Pharmaceuticals Inc. (IPIX)

Stock Price: $0.2575 USD -0.0025 (-0.96%)
Updated Apr 16, 2021 3:58 PM EDT - Market closed
Market Cap 111.68M
Revenue (ttm) 23,000
Net Income (ttm) -9.82M
Shares Out 418.07M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $0.2575
Previous Close $0.2600
Change ($) -0.0025
Change (%) -0.96%
Day's Open 0.2689
Day's Range 0.2530 - 0.2699
Day's Volume 745,440
52-Week Range 0.1160 - 0.6500

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's d...

4 days ago - GlobeNewsWire

WAKEFIELD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral data related to B...

1 week ago - GlobeNewsWire

WAKEFIELD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that an independent Data Monitor...

1 week ago - GlobeNewsWire

WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learni...

1 month ago - GlobeNewsWire

WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now participa...

1 month ago - GlobeNewsWire

WAKEFIELD, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company's Phase 2 clinic...

2 months ago - GlobeNewsWire

Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month

3 months ago - GlobeNewsWire

WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent preliminar...

4 months ago - GlobeNewsWire

About IPIX

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Cha... [Read more...]

Industry
Biotechnology
Stock Exchange
OTCMKTS
Ticker Symbol
IPIX
Full Company Profile

Financial Performance

Financial Statements